1. Medtech Insight
  2. >>Device Area

IMU Biosciences Joins £20M UK Government-Backed Cancer Immunoprofiling Project

 
• By Natasha Barrow

IMU Biosciences joins a UK consortium of 27 academic and industry partners to undertake “immunoprofiling” of 6,000 cancer patients to assess their response to treatment.

Immune Cells
Immune Cells (Shutterstock)

A nationwide multi-million cancer immunotherapy project was launched last month in the UK. The project, titled Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity (MANIFEST), is supported by over £20m (~$25m) in government and industry funding and involves 16 UK academic institutions and 11 industry partners.

The initiative will profile the immune systems of 6,000 patients with breast, bladder, kidney, and skin cancer. Half of the cohort are patients who have completed therapy; the other half...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostics

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.